Magle Chemoswed Holding AB (publ) engages in researching, developing, and manufacturing in the areas of medicinal chemistry and pharmaceutical technology in Sweden, Switzerland, rest of Europe, the United States, Brazil, and internationally. It offers degradable starch microsphere and dextran products; and active pharmaceutical ingredients, as well as engages in the research, development, manufacture, market, and sale of diagnostics products to hospitals, clinics, and pharmacies; and contract development and manufacturing organization activities. The company also provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, an antipsychotic agent; and isradipine, a calcium channel blocker used to treat hypertension. In addition, it offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company's microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures. Further, the company is developing EmboCept M for the treatment of benign prostatic hyperplasia; EmboCept L for the treatment of uterine fibroids; SmartGel II, an advanced wound care hydrogel for the removal and prevention of wound biofilm; and SmartBone, an advanced formulation of microspheres in combination with active ingredients for stimulation of bone growth in surgical implant procedures. Additionally, it develops and produces stem cell-based therapies for investigational and GMP use; and provides consulting services in materials and solid phase analysis services. Magle Chemoswed Holding AB (publ) was founded in 1944 and is based in Malmö, Sweden.